The deal involving the Irish company sees existing investors Fidelity Growth Partners Europe and General Catalyst Partners exit.
QUMAS works with pharmaceutical, biotechnology and medial device companies to provide regulatory, quality and compliance software services.
More on Fidelity Growth Partners Europe:
- Simon Clark: Striving for easier fundraising
- Davor Hebel on the entrepreneurial age: Does it really matter?
- Series D round worth £10 million for notonthehighstreet.com
The acquisition is said by Accelrys to extend its informatics portfolio by adding ‘mission-critical, end-to-end document and process management’ services.
Kevin O’Leary, CEO of QUMAS, comments, ‘In connecting science to business and in bridging the scientific and business communities through our compliance and quality solutions, QUMAS is delighted to join forces with Accelrys.
‘Joining the market leader in scientific innovation lifestyle management enables QUMAS to extend it strong customer momentum into other business areas currently being service by Accelrys.’
O’Leary, who was shortlisted as Entrepreneur of the Year by EY in 2009, was part of the launch team at QUMAS back in 2004 before moving to the US to establish a presence there in 1997. Having returned to Ireland in 2002, he then went on to become CEO in 2007.
From its bases in Cork and Jersey City in the US, QUMAS reported revenues of €14 million for the last financial year.
Accelrys president and CEO Max Carnecchia says. ‘Integrating QUMAS solutions into the Accelrys product portfolio will provide a single-vendor SILM solution that is already in high demand for product lifecycle management into the critical compliance and quality management arena for science-based process industries.’